Enroll your school in the ARESTIN Student Access Program

3 steps to enroll your school and to request samples

Step 1

Download, print, and fill out the ARESTIN Student Trial Kit Sample Request Form. This request form must be filled out and signed by the licensed dentist associated with your program. Email or fax the completed request form along with a copy of the Program Dentist’s valid dental license.

Step 2

Enter the information below and click the "Enroll My School" button at the bottom of the page.

Step 3

Once enrolled, a representative will reach out to you to schedule your ARESTIN 101 webinar for faculty and students.

When the webinar is completed, you will receive your faculty guides, laboratory guides, and samples of ARESTIN for clinical use.

Your submission is missing information. Please fill in the red fields below.

School Information

(Fields marked with an * are required.)

Your submission is missing information. Please fill in the red fields below.

School Information

(Fields marked with an * are required.)

School Name

Program Director First Name

Program Director Last Name

Number of Trial Kits 1 per senior student

Program Director Email

Program Faculty Contact Name

Program Faculty Contact Email

Primary Phone Number

Program Dentist Name

Program Dentist Email

Shipping Information

(Fields marked with an * are required.)

Shipping Information

(Fields marked with an * are required.)

Program Dentist Name

Address 1

Address 2

City

State

Zip Code

Fax Number

Questions? Contact us at 1-866-273-7846 or studentaccess@orapharma.com.

The ARESTIN Student Access Program is sponsored by OraPharma, a division of Bausch Health US, LLC.

IMPORTANT SAFETY INFORMATION AND INDICATION

ARESTIN^® (minocycline HCl) is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.

See Less

IMPORTANT SAFETY INFORMATION AND INDICATION

ARESTIN^® (minocycline HCl) is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, diagnostic tests should be performed and ARESTIN treatment discontinued.
The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

ARESTIN^® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN^® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

Click here for full Prescribing Information.